Switch to:
Also traded in: Austria, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.14
XRAY's Cash-to-Debt is ranked lower than
85% of the 205 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. XRAY: 0.14 )
Ranked among companies with meaningful Cash-to-Debt only.
XRAY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.08 Max: No Debt
Current: 0.14
0
No Debt
Equity-to-Asset 0.59
XRAY's Equity-to-Asset is ranked higher than
56% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. XRAY: 0.59 )
Ranked among companies with meaningful Equity-to-Asset only.
XRAY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.52 Max: 0.8
Current: 0.59
0.22
0.8
Debt-to-Equity 0.34
XRAY's Debt-to-Equity is ranked higher than
63% of the 142 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.37 vs. XRAY: 0.34 )
Ranked among companies with meaningful Debt-to-Equity only.
XRAY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.07  Med: 0.43 Max: 2.19
Current: 0.34
0.07
2.19
Debt-to-EBITDA -1.26
XRAY's Debt-to-EBITDA is ranked lower than
99.99% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. XRAY: -1.26 )
Ranked among companies with meaningful Debt-to-EBITDA only.
XRAY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.32  Med: 2.11 Max: 4.59
Current: -1.26
-1.32
4.59
Interest Coverage 11.43
XRAY's Interest Coverage is ranked lower than
99.99% of the 137 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.92 vs. XRAY: 11.43 )
Ranked among companies with meaningful Interest Coverage only.
XRAY' s Interest Coverage Range Over the Past 10 Years
Min: 7.17  Med: 11.22 Max: 17.73
Current: 11.43
7.17
17.73
Piotroski F-Score: 4
Altman Z-Score: 1.61
Beneish M-Score: -2.69
WACC vs ROIC
5.67%
5.35%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 10.67
XRAY's Operating Margin % is ranked lower than
81% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.41 vs. XRAY: 10.67 )
Ranked among companies with meaningful Operating Margin % only.
XRAY' s Operating Margin % Range Over the Past 10 Years
Min: 10.67  Med: 15.15 Max: 18.82
Current: 10.67
10.67
18.82
Net Margin % -41.40
XRAY's Net Margin % is ranked lower than
81% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.18 vs. XRAY: -41.40 )
Ranked among companies with meaningful Net Margin % only.
XRAY' s Net Margin % Range Over the Past 10 Years
Min: -41.4  Med: 10.89 Max: 12.94
Current: -41.4
-41.4
12.94
ROE % -26.78
XRAY's ROE % is ranked lower than
73% of the 198 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.43 vs. XRAY: -26.78 )
Ranked among companies with meaningful ROE % only.
XRAY' s ROE % Range Over the Past 10 Years
Min: -26.78  Med: 13.28 Max: 18.29
Current: -26.78
-26.78
18.29
ROA % -16.79
XRAY's ROA % is ranked lower than
72% of the 206 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.85 vs. XRAY: -16.79 )
Ranked among companies with meaningful ROA % only.
XRAY' s ROA % Range Over the Past 10 Years
Min: -16.79  Med: 6.35 Max: 10.31
Current: -16.79
-16.79
10.31
ROC (Joel Greenblatt) % -105.18
XRAY's ROC (Joel Greenblatt) % is ranked lower than
77% of the 204 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.63 vs. XRAY: -105.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
XRAY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -105.18  Med: 37.76 Max: 82.31
Current: -105.18
-105.18
82.31
3-Year Revenue Growth Rate -4.90
XRAY's 3-Year Revenue Growth Rate is ranked lower than
76% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.10 vs. XRAY: -4.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
XRAY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -6  Med: 11 Max: 42.9
Current: -4.9
-6
42.9
GuruFocus has detected 2 Warning Signs with Dentsply Sirona Inc XRAY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» XRAY's 30-Y Financials

Financials (Next Earnings Date: 2019-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

XRAY Guru Trades in

Q1 2018

XRAY Guru Trades in Q1 2018

Joel Greenblatt 88,162 sh (New)
Steven Cohen 100,000 sh (New)
Jim Simons 1,405,058 sh (New)
Ray Dalio 75,346 sh (New)
Andreas Halvorsen 9,241,223 sh (+71.21%)
Paul Tudor Jones 102,352 sh (+1104.28%)
Chuck Royce 105,185 sh (unchged)
Jerome Dodson 455,000 sh (unchged)
Vanguard Health Care Fund Sold Out
Daniel Loeb Sold Out
Ruane Cunniff 38,852 sh (-99.56%)
Pioneer Investments 238,165 sh (-67.13%)
Mario Gabelli 106,830 sh (-4.79%)
» More
Q2 2018

XRAY Guru Trades in Q2 2018

First Eagle Investment 1,481,354 sh (New)
Jim Simons 1,501,658 sh (+6.88%)
Chuck Royce 105,185 sh (unchged)
Joel Greenblatt Sold Out
Steven Cohen Sold Out
Ray Dalio Sold Out
Jerome Dodson Sold Out
Ruane Cunniff 29,241 sh (-24.74%)
Andreas Halvorsen 984,025 sh (-89.35%)
Paul Tudor Jones 43,302 sh (-57.69%)
Pioneer Investments 184,787 sh (-22.41%)
Mario Gabelli 104,930 sh (-1.78%)
» More
Q3 2018

XRAY Guru Trades in Q3 2018

Ray Dalio 21,985 sh (New)
Joel Greenblatt 248,071 sh (New)
Jeff Ubben 2,200,000 sh (New)
Mario Gabelli 105,130 sh (+0.19%)
First Eagle Investment 6,155,959 sh (+315.56%)
Ruane Cunniff 29,380 sh (+0.48%)
Paul Tudor Jones 165,123 sh (+281.33%)
Andreas Halvorsen Sold Out
Chuck Royce 73,200 sh (-30.41%)
Jim Simons 413,658 sh (-72.45%)
Pioneer Investments 151,996 sh (-17.75%)
» More
» Details

Insider Trades

Latest Guru Trades with XRAY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339114    SIC: 3843
Compare:NYSE:COO, XSWX:STMN, NAS:HOLX, TSE:7733, NYSE:RMD, NYSE:MTD, NYSE:STE, NYSE:WAT, SZSE:002294, NYSE:WST, NYSE:HRC, NAS:ICUI, NAS:PODD, NYSE:CMD, OCSE:COLO B, TSE:7747, NYSE:HAE, MIL:AMP, OSTO:LIFCO B, TSE:4543 » details
Traded in other countries:XRAY.Austria, DY2.Germany, 0I8F.UK,
Headquarter Location:USA
Dentsply Sirona Inc is a designer, developer, manufacturer and marketer of consumable dental products for the professional dental market. It also manufactures and markets other consumable medical device products.

Dentsply Sirona is one of the world's largest manufacturers and distributors of dental supplies and equipment. Its product segments include dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. Over half of its products are sold through dental distributors, and approximately 65% of Dentsply's sales are outside the U.S.

Guru Investment Theses on Dentsply Sirona Inc

Jerome Dodson Comments on Dentsply Sirona - Apr 23, 2018

We believe that investors over-reacted to the bad news, so we took advantage of the opportunity and increased our position at bargain-basement prices. Dentsply Sirona (NASDAQ:XRAY) is one of the largest manufacturers of dental equipment and consumables. Its stock sank 23.6% from $65.83 to $50.31, cutting 63 basis points from the Fund’s return. Investors were surprised by the company’s decision to replace its interim CEO, which followed broader turnover at the end of last year. Shares fell further after the company provided lower than expected earnings guidance, reflecting increased investments in its sales force and product development. Despite the recent challenges, we believe the newly appointed management team is focusing on the right strategic actions to deliver sustainable growth over the long-term. We expect the stock to rebound as the company benefits from its sales force investments, a robust pipeline of innovative imaging and implant offerings, and synergies between its Sirona and Dentsply segments.

From Jerome Dodson (Trades, Portfolio)'s first-quarter 2018 Parnassus Fund shareholder letter.

Check out Jerome Dodson latest stock trades

Ruane Cunniff Comments on Dentsply Sirona - Mar 06, 2018

Dentsply Sirona (NASDAQ:XRAY) had a frustratingly eventful year. Although full-year profits are expected to be down only modestly, the company’s decision to open up its historically exclusive distribution setup in its US equipment business, however wise, resulted in massive short-term disruption. This disruption was at least partly responsible for the $1.2 billion non-cash impairment charge it took in the second quarter. In October, Dentsply Sirona announced that CEO Jeff Slovin and executive chairman Bret Wise had both tendered their resignations. Mark Thierer, a respected executive in the pharmacy benefit management space, was named as interim CEO. In January, Dentsply Sirona announced that Don Casey, formerly of Cardinal Health and Johnson & Johnson, would become its permanent CEO. On top of all this, growth in the global dental market was anemic this past year.



Dentsply Sirona still has a very high quality business, both in terms of profitability and durability. The relative stability of the business through the events of this past year is a testament to this fact. However, the lack of management stability is an unqualified negative. We will be monitoring the situation closely.

From Ruane Cunniff (Trades, Portfolio)'s Sequoia Fund 4th Quarter 2017 Manager's Commentary.

Check out Ruane Cunniff latest stock trades

Jerome Dodson Comments on Dentsply Sirona - Oct 25, 2017

Dentsply Sirona (NASDAQ:XRAY) is the leading manufacturer of dental consumables and equipment. The stock sold off due to distribution problems involving fellow Parnassus Fund’s holding Patterson Companies. We believe these issues are temporary, so we used the weakness as an opportunity to add Dentsply Sirona to the portfolio at what we believe is an attractive valuation.


From Jerome Dodson (Trades, Portfolio)'s Parnassus Fund third quarter 2017 commentary.

Check out Jerome Dodson latest stock trades

Top Ranked Articles about Dentsply Sirona Inc

DENTSPLY SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dentsply Sirona, Inc. - XRAY
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dentsply Sirona, Inc. (XRAY) and Lead Plaintiff Deadline - February 19, 2019
INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Dentsply Sirona, Inc. Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of XRAY, NVDA and AGN
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dentsply Sirona, Inc. (XRAY) and Lead Plaintiff Deadline: February 19, 2019
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Dentsply Sirona, Inc. Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
DENTSPLY SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dentsply Sirona, Inc. - XRAY
Hagens Berman Notifies Dentsply Sirona (NASDAQ: XRAY) Investors of Securities Fraud Lawsuit and February 19, 2019 Lead Plaintiff Deadline
UPDATE – SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Dentsply Sirona, Inc. (XRAY) and Lead Plaintiff Deadline: February 19, 2019
DENTSPLY SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Dentsply Sirona, Inc. - XRAY

Ratios

vs
industry
vs
history
Forward PE Ratio 18.55
XRAY's Forward PE Ratio is ranked higher than
77% of the 40 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 26.32 vs. XRAY: 18.55 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 1.77
XRAY's PB Ratio is ranked higher than
67% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.45 vs. XRAY: 1.77 )
Ranked among companies with meaningful PB Ratio only.
XRAY' s PB Ratio Range Over the Past 10 Years
Min: 1.49  Med: 2.62 Max: 4.11
Current: 1.77
1.49
4.11
PS Ratio 2.31
XRAY's PS Ratio is ranked higher than
51% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.48 vs. XRAY: 2.31 )
Ranked among companies with meaningful PS Ratio only.
XRAY' s PS Ratio Range Over the Past 10 Years
Min: 1.58  Med: 2.35 Max: 4.03
Current: 2.31
1.58
4.03
Price-to-Free-Cash-Flow 26.86
XRAY's Price-to-Free-Cash-Flow is ranked higher than
57% of the 74 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.61 vs. XRAY: 26.86 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
XRAY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 12.38  Med: 19.76 Max: 35.44
Current: 26.86
12.38
35.44
Price-to-Operating-Cash-Flow 17.60
XRAY's Price-to-Operating-Cash-Flow is ranked lower than
53% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.15 vs. XRAY: 17.60 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
XRAY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.42  Med: 15.28 Max: 26.51
Current: 17.6
10.42
26.51
EV-to-EBIT -6.19
XRAY's EV-to-EBIT is ranked lower than
99.99% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.93 vs. XRAY: -6.19 )
Ranked among companies with meaningful EV-to-EBIT only.
XRAY' s EV-to-EBIT Range Over the Past 10 Years
Min: -23.6  Med: 18.3 Max: 39.2
Current: -6.19
-23.6
39.2
EV-to-EBITDA -7.70
XRAY's EV-to-EBITDA is ranked lower than
99.99% of the 138 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.49 vs. XRAY: -7.70 )
Ranked among companies with meaningful EV-to-EBITDA only.
XRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -41.4  Med: 14.1 Max: 27.1
Current: -7.7
-41.4
27.1
EV-to-Revenue 2.64
XRAY's EV-to-Revenue is ranked lower than
51% of the 199 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.57 vs. XRAY: 2.64 )
Ranked among companies with meaningful EV-to-Revenue only.
XRAY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.7  Med: 2.7 Max: 5.2
Current: 2.64
1.7
5.2
Shiller PE Ratio 64.85
XRAY's Shiller PE Ratio is ranked higher than
56% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.97 vs. XRAY: 64.85 )
Ranked among companies with meaningful Shiller PE Ratio only.
XRAY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.1  Med: 25.65 Max: 72.32
Current: 64.85
18.1
72.32
Current Ratio 1.76
XRAY's Current Ratio is ranked lower than
62% of the 200 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.57 vs. XRAY: 1.76 )
Ranked among companies with meaningful Current Ratio only.
XRAY' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 1.88 Max: 4.36
Current: 1.76
1.2
4.36
Quick Ratio 1.14
XRAY's Quick Ratio is ranked lower than
60% of the 201 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.87 vs. XRAY: 1.14 )
Ranked among companies with meaningful Quick Ratio only.
XRAY' s Quick Ratio Range Over the Past 10 Years
Min: 0.63  Med: 1.08 Max: 2.98
Current: 1.14
0.63
2.98
Days Inventory 127.37
XRAY's Days Inventory is ranked higher than
55% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.35 vs. XRAY: 127.37 )
Ranked among companies with meaningful Days Inventory only.
XRAY' s Days Inventory Range Over the Past 10 Years
Min: 89.71  Med: 102.66 Max: 127.37
Current: 127.37
89.71
127.37
Days Sales Outstanding 63.78
XRAY's Days Sales Outstanding is ranked lower than
59% of the 165 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.97 vs. XRAY: 63.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
XRAY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 53.28  Med: 58.48 Max: 68.2
Current: 63.78
53.28
68.2
Days Payable 55.84
XRAY's Days Payable is ranked lower than
52% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 54.66 vs. XRAY: 55.84 )
Ranked among companies with meaningful Days Payable only.
XRAY' s Days Payable Range Over the Past 10 Years
Min: 34.96  Med: 40.22 Max: 57.51
Current: 55.84
34.96
57.51

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.87
XRAY's Dividend Yield % is ranked lower than
76% of the 164 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.16 vs. XRAY: 0.87 )
Ranked among companies with meaningful Dividend Yield % only.
XRAY' s Dividend Yield % Range Over the Past 10 Years
Min: 0.4  Med: 0.55 Max: 1.03
Current: 0.87
0.4
1.03
3-Year Dividend Growth Rate 9.70
XRAY's 3-Year Dividend Growth Rate is ranked higher than
53% of the 62 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.90 vs. XRAY: 9.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
XRAY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 7.4 Max: 37.5
Current: 9.7
0
37.5
Forward Dividend Yield % 0.87
XRAY's Forward Dividend Yield % is ranked lower than
83% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.30 vs. XRAY: 0.87 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.34
XRAY's 5-Year Yield-on-Cost % is ranked lower than
71% of the 209 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. XRAY: 1.34 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
XRAY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.62  Med: 0.85 Max: 1.59
Current: 1.34
0.62
1.59
3-Year Average Share Buyback Ratio -17.20
XRAY's 3-Year Average Share Buyback Ratio is ranked lower than
80% of the 143 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -5.00 vs. XRAY: -17.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
XRAY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -67.6  Med: 0.3 Max: 2.2
Current: -17.2
-67.6
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.16
XRAY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
76% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. XRAY: 1.16 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
XRAY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.95  Med: 1.41 Max: 7.53
Current: 1.16
0.95
7.53
Price-to-Median-PS-Value 0.98
XRAY's Price-to-Median-PS-Value is ranked lower than
64% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.13 vs. XRAY: 0.98 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
XRAY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.37  Med: 0.92 Max: 1.68
Current: 0.98
0.37
1.68
Earnings Yield (Greenblatt) % -16.16
XRAY's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 207 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.40 vs. XRAY: -16.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
XRAY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.6  Med: 5.1 Max: 10.4
Current: -16.16
-18.6
10.4
Forward Rate of Return (Yacktman) % 6.90
XRAY's Forward Rate of Return (Yacktman) % is ranked lower than
65% of the 101 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.66 vs. XRAY: 6.90 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
XRAY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 4.7  Med: 11.2 Max: 16.3
Current: 6.9
4.7
16.3

More Statistics

Revenue (TTM) (Mil) $4,017.60
EPS (TTM) $ -7.34
Beta0.59
Volatility28.41%
52-Week Range $33.93 - 63.03
Shares Outstanding (Mil)222.55

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 3,949 4,016 4,166
EBIT (Mil $) -43 610 775
EBITDA (Mil $) 222 872 1,005
EPS ($) -2.20 1.77 2.22
EPS without NRI ($) -2.20 1.77 2.22
EPS Growth Rate
(Future 3Y To 5Y Estimate)
6.91%
Dividends per Share ($) 0.35 0.36 0.39

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}